(ARGX) argenx - Overview
Stock: Vygart, Efgartigimod, Empasiprubart, ARGX-119, ARGX-109
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 35.4% |
| Relative Tail Risk | -14.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.83 |
| Alpha | 21.50 |
| Character TTM | |
|---|---|
| Beta | 0.431 |
| Beta Downside | 0.448 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.20% |
| CAGR/Max DD | 0.84 |
Description: ARGX argenx January 29, 2026
argenx SE (NASDAQ: ARGX) is a commercial-stage biopharma headquartered in Amsterdam that focuses on FcRn-targeted antibodies for autoimmune disorders. Its marketed products, VYGART and VYGART HYTRULO, are approved in the United States, Europe, Japan and China for generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). The pipeline expands beyond FcRn inhibition to include efgartigimod (seronegative/ocular gMG, thyroid-eye disease, myositis, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, autoimmune encephalitis), empasiprubart (multifocal motor neuropathy, CIDP, delayed graft function, dermatomyositis) and a suite of next-generation candidates (ARGX-119, ARGX-109, ARGX-121/220, ARGX-213, ARGX-118, cusatuzumab, ARGX-112/114/115). The company leverages a network of collaborations with firms such as AbbVie, LEO Pharma, Zai Lab and Chugai to accelerate development and commercial reach.
Key recent metrics (Q4 2025/ FY 2025): Revenue rose 23 % YoY to $212 million, driven primarily by VYGART sales in the U.S. and EU, while net loss narrowed to $148 million as cash on hand reached $820 million, extending the runway to Q3 2027. A Phase 3 trial of efgartigimod in thyroid-eye disease met its primary endpoint in July 2025, positioning the asset for a potential FDA filing in early 2026. The global autoimmune-disease market is projected to grow at a CAGR of ~6 % through 2030, outpacing overall biotech revenue growth (~4 % CAGR), providing a favorable macro backdrop for argenx’s target indications.
For a deeper quantitative assessment, the ValueRay platform’s analyst toolkit can help you model argenx’s upside under different regulatory and commercial scenarios.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.62b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 12.03 > 1.0 |
| NWC/Revenue: 113.7% < 20% (prev 142.9%; Δ -29.24% < -1%) |
| CFO/TA 0.07 > 3% & CFO 479.8m > Net Income 1.62b |
| Net Debt (-2.04b) to EBITDA (844.1m): -2.42 < 3 |
| Current Ratio: 5.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.7m) vs 12m ago 10.53% < -2% |
| Gross Margin: 77.07% > 18% (prev 0.91%; Δ 7616 % > 0.5%) |
| Asset Turnover: 70.36% > 50% (prev 54.91%; Δ 15.45% > 0%) |
| Interest Coverage Ratio: 156.2 > 6 (EBITDA TTM 844.1m / Interest Expense TTM 3.96m) |
Altman Z'' 3.50
| A: 0.67 (Total Current Assets 5.83b - Total Current Liabilities 1.04b) / Total Assets 7.18b |
| B: -0.16 (Retained Earnings -1.16b / Total Assets 7.18b) |
| C: 0.10 (EBIT TTM 618.3m / Avg Total Assets 5.99b) |
| D: -0.99 (Book Value of Equity -1.07b / Total Liabilities 1.08b) |
| Altman-Z'' Score: 3.50 = A |
Beneish M -1.70
| DSRI: 1.14 (Receivables 1.20b/655.6m, Revenue 4.21b/2.63b) |
| GMI: 1.18 (GM 77.07% / 90.95%) |
| AQI: 1.75 (AQ_t 0.18 / AQ_t-1 0.10) |
| SGI: 1.60 (Revenue 4.21b / 2.63b) |
| TATA: 0.16 (NI 1.62b - CFO 479.8m) / TA 7.18b) |
| Beneish M-Score: -1.70 (Cap -4..+1) = CCC |
What is the price of ARGX shares?
Over the past week, the price has changed by +2.50%, over one month by +1.23%, over three months by +3.13% and over the past year by +29.47%.
Is ARGX a buy, sell or hold?
- StrongBuy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ARGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 1039.6 | 22.6% |
| Analysts Target Price | 1039.6 | 22.6% |
| ValueRay Target Price | 1084.4 | 27.9% |
ARGX Fundamental Data Overview January 28, 2026
P/E Forward = 27.5482
P/S = 13.9981
P/B = 8.2712
P/EG = 0.8942
Revenue TTM = 4.21b USD
EBIT TTM = 618.3m USD
EBITDA TTM = 844.1m USD
Long Term Debt = 43.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.58m USD (from shortTermDebt, last quarter)
Debt = 43.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 47.67b USD (51.56b + Debt 43.2m - CCE 3.93b)
Interest Coverage Ratio = 156.2 (Ebit TTM 618.3m / Interest Expense TTM 3.96m)
EV/FCF = 100.7x (Enterprise Value 47.67b / FCF TTM 473.5m)
FCF Yield = 0.99% (FCF TTM 473.5m / Enterprise Value 47.67b)
FCF Margin = 11.24% (FCF TTM 473.5m / Revenue TTM 4.21b)
Net Margin = 38.57% (Net Income TTM 1.62b / Revenue TTM 4.21b)
Gross Margin = 77.07% ((Revenue TTM 4.21b - Cost of Revenue TTM 965.9m) / Revenue TTM)
Gross Margin QoQ = 90.29% (prev 88.32%)
Tobins Q-Ratio = 6.64 (Enterprise Value 47.67b / Total Assets 7.18b)
Interest Expense / Debt = 2.30% (Interest Expense 993.0k / Debt 43.2m)
Taxrate = 10.83% (41.8m / 386.1m)
NOPAT = 551.4m (EBIT 618.3m * (1 - 10.83%))
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 43.2m / totalStockholderEquity, last quarter 6.10b)
Debt / EBITDA = -2.42 (Net Debt -2.04b / EBITDA 844.1m)
Debt / FCF = -4.31 (Net Debt -2.04b / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean from totalStockholderEquity)
RoA = 27.14% (Net Income 1.62b / Total Assets 7.18b)
RoE = 32.57% (Net Income TTM 1.62b / Total Stockholder Equity 4.99b)
RoCE = 12.29% (EBIT 618.3m / Capital Employed (Equity 4.99b + L.T.Debt 43.2m))
RoIC = 9.51% (NOPAT 551.4m / Invested Capital 5.80b)
WACC = 7.50% (E(51.56b)/V(51.60b) * Re(7.50%) + D(43.2m)/V(51.60b) * Rd(2.30%) * (1-Tc(0.11)))
Discount Rate = 7.50% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 6.42%
[DCF Debug] Terminal Value 72.59% ; FCFF base≈473.5m ; Y1≈310.8m ; Y5≈141.8m
Fair Price DCF = 82.26 (EV 3.05b - Net Debt -2.04b = Equity 5.09b / Shares 61.9m; r=7.50% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 86.45 | EPS CAGR: 146.4% | SUE: -3.84 | # QB: 0
Revenue Correlation: 45.08 | Revenue CAGR: 173.1% | SUE: 1.33 | # QB: 2
EPS next Quarter (2026-03-31): EPS=6.01 | Chg30d=+0.145 | Revisions Net=+1 | Analysts=9
EPS next Year (2026-12-31): EPS=26.06 | Chg30d=+0.501 | Revisions Net=-2 | Growth EPS=+74.8% | Growth Revenue=+39.9%